DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION
Activist investor DOMA Perpetual Capital Management, holding a 7.5% stake in Pacira BioSciences, has launched a proxy fight to replace the current board of directors. DOMA accuses the board of gross negligence and value destruction, citing a decade of share price declines and a failure to adequately protect EXPAREL’s patent portfolio against generic competition.
Key figures
- 1yr return
- -9%
- 2yr return
- -21%
- 3yr return
- -41%
- 5yr return
- -65%
- Ytd return
- -10%
- 10yr return
- -46%
- Activist stake pct
- 7.5%
- Exparel revenue concentration
- 80%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.